咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Neoadjuvant therapy for resect... 收藏

Neoadjuvant therapy for resectable pancreatic cancer

Neoadjuvant therapy for resectable pancreatic cancer

作     者:Sheikh Hasibur Rahman Robin Urquhart Michele Molinari 

作者机构:Department of Surgery Dalhousie University Department of Surgery University of Pittsburgh Medical Center 

出 版 物:《World Journal of Gastrointestinal Oncology》 (世界胃肠肿瘤学杂志(英文版)(电子版))

年 卷 期:2017年第9卷第12期

页      面:457-465页

核心收录:

学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基  金:Stefanie Condon-Oldreive founder and director of Craig’s Cause Pancreatic Cancer Society (www.craigscause.ca) for the research scholarship that supported Dr. Sheikh Hasibur Raman while working on this project 

主  题:Pancreatic adenocarcinoma Neoadjuvant chemotherapy Neoadjuvant chemoradiation therapy Meta-analysis Decision analysis Borderline resectable Locally advanced Randomized controlled trial Phase I trial Phase II trial Phase III trial 

摘      要:The use of neoadjuvant therapies has played a major role for borderline resectable and locally advanced pancreatic cancers(PCs). For this group of patients, preoperative chemotherapy or chemoradiation has increased the likelihood of surgery with negative resection margins and overall survival. On the other hand, for patients with resectable PC, the main rationale for neoadjuvant therapy is that the overall survival with current strategies is unsatisfactory. There is a consensus that we need new treatments to improve the overall survival and quality of life of patients with PC. However, without strong scientific evidence supporting the theoretical advantages of neoadjuvant therapies, these potential benefits might turn out not to be worth the risk of tumors progression while waiting for surgery. The focus of this paper is to provide the readers an overview of the most recent evidence on this subject.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分